What are the advantages and efficacy of adagrasib in treating lung cancer?

The advantages of adagrasib in the treatment of lung cancer mainly include breakthrough therapy designation, high objective response rate, high disease control rate, improved survival, targeting specific mutations, and penetrating the brain-blood barrier. It has good efficacy in the treatment of lung cancer.

What is Adagrasib?

is a RAS GT enzyme family inhibitor and a targeted therapy for non-small cell lung cancer (NSCLC) with KRAS G12C mutations.

Advantages of adagrasib in the treatment of lung cancer

1. Breakthrough therapy designation: Due to its outstanding performance in clinical trials, adagrasib was awarded "breakthrough therapy" designation by the US FDA and was marketed through the accelerated approval channel.

2. High objective response rate: In clinical trials, the objective response rate (ORR) of adagrasib in the treatment of non-small cell lung cancer reached 43%, indicating that more than 40% of patients have reduced tumor size after receiving treatment.

3. High disease control rate: The disease control rate (DCR) of adagrasib is as high as 79.5%, indicating that most patients have their disease under control after receiving treatment and their condition has not worsened further.

4. Improved survival: Studies have shown that the median progression-free survival (PFS) of patients treated with adagrasib is 6.5 months, and the median overall survival (OS) is as long as 12.6 months, indicating that adagrasib can significantly extend the survival time of patients.

5. Targeting specific mutations: Adagrasib specifically targets the KRAS G12C mutation, which is a common mutation type in non-small cell lung cancer. It provides a new treatment option for patients carrying such mutations.

6. Can penetrate the brain-blood barrier: Adagraceb is an oral drug that has been proven to effectively penetrate the blood-brain barrier and has a good therapeutic effect on brain metastases in patients with non-small cell lung cancer carrying KRAS G12C mutations.

Efficacy of adagrasib in the treatment of lung cancer

In a registered phase 2 cohort study, 116 patients with KRASG12C-mutant non-small cell lung cancer (NSCLC) who had previously received platinum-containing chemotherapy and anti-programmed death 1 or programmed death ligand 1 therapy were treated with adagrasib (600 mg twice daily).

After a median follow-up of 12.9 months, 98.3% of the patients had previously received chemotherapy and immunotherapy. The median duration of response was 8.5 months and the median progression-free survival was 6.5 months. With a median follow-up of 15.6 months, the patients' median overall survival was 12.6 months. Among 33 patients with previously treated stable CNS metastases, the intracranially confirmed objective response rate was 33.3%.

Adagrasib showed clinical efficacy and no new safety signals in patients who had previously been treated for KRASG12C mutated non-small cell lung cancer.

The price of Adagrasib

1. Laos Lucius version: The specification of a box is 200mg*90 tablets. The current reference price of a box is about 6000$-6500$.

2. Original research version: The specification of a box is 200mg*180 capsules, and the current price is approximately between 210,450$-243,800$.

Recommended usage and dosage of adagrasib

The recommended dose is 600 mg, taken twice a day. It needs to be taken at the same time every day, and can be taken with or without food.

(Note: The above dosage and administration reference are from the U.S. FDA drug instructions. The usage and dosage are for reference only. The specific dosage needs to be subject to medical advice)

Summary

Although adagrasib has certain advantages in treating lung cancer, side effects such as nausea, diarrhea, vomiting, fatigue, musculoskeletal pain, and loss of appetite may occur after taking the drug. Therefore, patients should take the drug under the guidance of a doctor and closely monitor the efficacy and safety of the drug.

References:

Jänne PA, Riely GJ, Gadgeel SM, Heist RS, Ou SI, Pacheco JM, Johnson ML, Sabari JK, Leventakos K, Yau E, Bazhenova L, Negrao MV, Pennell NA, Zhang J, Anderes K, Der-Torossian H, Kheoh T, Velastegui K, Yan X, Christensen JG, Chao RC, Spira AI. Adagrasib in Non-Small-Cell Lung Cancer Harboring a KRASG12C Mutation. N Engl J Med. 2022 Jul 14;387(2):120-131. doi: 10.1056/NEJMoa2204619. Epub 2022 Jun 3. PMID: 35658005.

Related hot article recommendations: